TFFP Profile
TFF Pharmaceuticals, Inc. is a biofarmaceutical company focused on developing and commercializing drug products using its patented Thin Film Freezing (TFF) technology platform. Based in Austin, Texas, and incorporated in 2018, the company aims to create inhaled dry powder drugs for treating pulmonary diseases and conditions. TFF Pharmaceuticals operates in the United States and Australia.
The company's leading drug candidates include TFF Voriconazole Inhalation Powder, currently in Phase II clinical trials for invasive pulmonary aspergillosis, and TFF Tacrolimus Inhalation Powder, also in Phase II trials for preventing lung transplant rejection. Additionally, TFF Pharmaceuticals is working on dry powder products for treating epilepsy syndromes, anxiety, insomnia, various pain conditions, and COVID-19 infections. Their product pipeline includes an inhaled SARS-CoV2 monoclonal antibody, Niclosamide Inhalation Powder for treating tapeworm infections and COVID-19, among other vaccines.
TFF Pharmaceuticals has established several key partnerships and agreements to advance its drug development efforts. These include a license agreement with the University of Texas at Austin for developing inhaled dry powder drugs, a joint development agreement with Augmenta Bioworks, Inc. for inhaled SARS-CoV2 monoclonal antibody, and a licensing and collaboration agreement with UNION therapeutics A/S. These collaborations enhance TFF Pharmaceuticals' ability to innovate and bring new treatments to market.
|
